We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Positron Emission Tomography in Prostate Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00121212
First Posted: July 21, 2005
Last Update Posted: October 30, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Washington University School of Medicine
  Purpose

RATIONALE: Diagnostic procedures, such as positron emission tomography using carbon-11 acetate, may help find metastases from prostate cancer and may help predict whether prostate cancer will come back after treatment.

PURPOSE: This clinical trial is studying how well positron emission tomography using carbon-11 acetate works in finding metastases and predicting recurrence in patients with prostate cancer who are at risk for recurrence after treatment.


Condition Intervention
Prostate Cancer Procedure: carbon-11 acetate PET scan

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Positron Emission Tomography in Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Determine the role of AC-PET in changing initial patient management [ Time Frame: Completion of patient treatment ]

Secondary Outcome Measures:
  • Determine the value of AC-PET in predicting recurrence [ Time Frame: Minimum of 2 years and maximum of 5 years ]
  • Assess the performance of AC-PET for detection of lymph node metastasis by comparison with biopsy. [ Time Frame: Minimum of 2 years and maximum of 5 years ]

Enrollment: 179
Study Start Date: July 2003
Study Completion Date: October 2015
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Surgery - Negative PET scan
If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
Procedure: carbon-11 acetate PET scan
Experimental: Surgery - Positive PET scan
If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
Procedure: carbon-11 acetate PET scan
Active Comparator: Radiation therapy Negative or Positive PET scan
If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
Procedure: carbon-11 acetate PET scan

Detailed Description:
The overall goal of this project is determination of the role of PET in patients with newly diagnosed medium- and high-risk prostate cancer in whom the standard clinical and imaging workup is negative. Thus, the incremental value of PET will be determined in this important group.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Newly diagnosed prostate cancer
  • Has completed conventional staging examinations, including biopsy with Gleason score, CT scan of the abdomen and pelvis, and whole-body bone scintigraphy AND conventional staging examinations negative
  • Candidate for curative radical prostatectomy OR curative radiotherapy OR staging lymphadenectomy prior to surgery
  • Deemed to be at medium or high risk for recurrence after initial curative treatment, as defined by 1 of the following criteria:

    • Gleason score 7 AND prostate-specific antigen (PSA) 10-20 ng/mL
    • Gleason score ≥ 8 AND PSA < 10 ng/mL
    • Gleason score ≥ 8 AND PSA > 10 ng/mL
    • Any Gleason score AND PSA > 20 ng/mL

Exclusion Therapy:

  • Not a candidate for treatment by surgery or radiation therapy with curative intent
  • Inability to give informed consent
  • Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of other cancer present within the last 5 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00121212


Locations
United States, Missouri
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
National Cancer Institute (NCI)
Investigators
Study Chair: Farrokh Dehdashti, MD Washington University Siteman Cancer Center
  More Information

Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00121212     History of Changes
Other Study ID Numbers: CDR0000434994
R01CA101734 ( U.S. NIH Grant/Contract )
P30CA091842 ( U.S. NIH Grant/Contract )
WU-03-0315
First Submitted: July 19, 2005
First Posted: July 21, 2005
Last Update Posted: October 30, 2015
Last Verified: October 2015

Keywords provided by Washington University School of Medicine:
stage I prostate cancer
stage IIB prostate cancer
stage IIA prostate cancer
stage III prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases